Trinity Biotech (TRIB) has released an update.
Trinity Biotech plc has unveiled its fourth quarter and full year 2023 financial outcomes alongside major business advancements, including a comprehensive plan to enhance financial performance through operational consolidation, cost reductions, and a strategic move to outsource manufacturing. The company is targeting a significant increase in EBITDASO by mid-2025, based solely on existing business growth, excluding new biosensor contributions. Trinity Biotech has also acquired biosensor assets, aiming to develop a groundbreaking continuous glucose monitor that promises affordability and improved data capture, with a strong focus on expanding their wearable biosensor business.
For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.
